RT Journal Article
SR Electronic
T1 Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.05.20226605
DO 10.1101/2020.11.05.20226605
A1 Yizhou Yu
A1 Marco Travaglio
A1 Rebeka Popovic
A1 Nuno Santos Leal
A1 L. Miguel Martins
YR 2020
UL http://medrxiv.org/content/early/2020/11/07/2020.11.05.20226605.abstract
AB In December 2019, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began infecting humans causing a novel disease, coronavirus disease 19 (COVID-19). This was first described in the Wuhan province of the People’s Republic of China. SARS-CoV-2 spread throughout the world causing a global pandemic. To date, thousands of cases of COVID-19 were reported in the United Kingdom, and over 45,000 patients have died. Some progress has been achieved in managing this disease, but the biological determinants of health, besides age, that affect COVID-19 infectivity and mortality are under scrutiny. Recent studies show that several medical conditions, including diabetes and hypertension, increase the risk of COVID-19 infection and death. The increased vulnerability of the elderly and those with comorbidities, together with the prevalence of neurodegenerative diseases with advanced age, led us to investigate the links between neurodegeneration and COVID-19. We analysed the primary health records of 13,338 UK individuals tested for COVID-19 between March and July 2020. We show that a pre-existing diagnosis of Alzheimer’s disease predicts the highest risk of COVID-19 infection and mortality among the elderly. In contrast, Parkinson’s disease patients were found to be at increased risk of infection but not mortality from COVID-19. We conclude that there are disease-specific differences in COVID-19 susceptibility among patients affected by neurodegenerative disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is funded by the UK Medical Research Council, intramural project MC_UU_00025/3 (RG94521)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank ethical approval was granted from the North West Multi-Centre Research Ethics Committee. The current analysis was approved under the UK Biobank application 60124All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode available in GitHub https://m1gus.github.io/AD_PD_COVID19/ ADAlzheimer’s diseaseCOPDChronic obstructive pulmonary diseaseCOVID-19Coronavirus disease-19PDParkinson’s diseaseSARS-CoV-2Severe acute respiratory syndrome coronavirus 2